```json
{
"content": [
{
"type": "paragraph",
"content": "North America dominates the Medications for Prurigo Nodularis market with a 45% share, driven by advanced healthcare infrastructure, high R&D investments, and rapid adoption of novel therapies. The region benefits from a mature ecosystem, supported by favorable FDA policies and a robust pipeline of biologics. Demographics also favor growth, with rising prevalence of chronic pruritus in aging populations."
},
{
"type": "paragraph",
"content": "Europe follows with a 30% share, fueled by progressive regulatory frameworks, strong public healthcare systems, and high patient awareness. Germany and France lead in market growth due to collaborations between pharma players and academic institutions. The region’s focus on orphan drug incentives accelerates innovation in niche therapies."
},
{
"type": "paragraph",
"content": The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of 12%, supported by increasing disease awareness, rising disposable incomes, and government investments in healthcare infrastructure. Japan and South Korea leverage advanced dermatological research, while India and China offer untapped potential due to their large patient pools."
},
{
"type": "paragraph",
"content": "Latin America and the Middle East & Africa collectively account for 15% of the regional forecast, with growth constrained by limited healthcare access and diagnostic challenges. However, emerging partnerships with global biotech firms and improving reimbursement policies in Brazil and Saudi Arabia are expected to drive incremental adoption of specialized treatments."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 45 },
{ "name": "Europe", "value": 30 },
{ "name": "Asia Pacific", "value": 15 },
{ "name": "Latin America", "value": 7 },
{ "name": "Middle East & Africa", "value": 3 }
]
}
}
```
